Integrin modulators: a patent review
Expert Opinion on Therapeutic Patents
2013
23
10
1273-1295
Caveolin-1-negative head and neck squamous cell carcinoma primary tumors display increased epithelial to mesenchymal transition and prometastatic properties
Oncotarget
2015
6
39
In Vivo PET Imaging of the Cancer Integrin αvβ6 Using
68
Ga-Labeled Cyclic RGD Nonapeptides
Journal of Nuclear Medicine
2016
58
4
671-677
Complementary, Selective PET Imaging of Integrin Subtypes 5 1 and v 3 Using 68Ga-Aquibeprin and 68Ga-Avebetrin
Journal of Nuclear Medicine
2015
57
3
460-466
Tumor Targeting via Integrin Ligands
Frontiers in Oncology
2013
3
Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging
Theranostics
2015
5
6
618-630
Comparison of cyclic RGD peptides for αvβ3 integrin detection in a rat model of myocardial infarction
EJNMMI Research
2013
3
1
38
FOSL1 Controls the Assembly of Endothelial Cells into Capillary Tubes by Direct Repression of αv and β3 Integrin Transcription
Molecular and Cellular Biology
2013
33
6
1198-1209
Investigation of early cell–surface interactions of human mesenchymal stem cells on nanopatterned β-type titanium–niobium alloy surfaces
Interface Focus
2014
4
1
20130046
Substrate engagement of integrins α5β1 and αvβ3 is necessary, but not sufficient, for high directional persistence in migration on fibronectin
Scientific Reports
2016
6
1